Neoadjuvant chemotherapy followed by surgery has been recommended as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, its efficacy remains to be improved. Drugs targeting PD-1/PD-L1 pathway have been proven to be effective for late-stage NSCLC, and anti-angiogenesis agents targeting VEGF (bevacizumab) has also been used for the first line treatment of advanced or metastatic NSCLC. Therefore, we conduct this single-arm clinical trial, which aims to investigate the safety and feasibility of neoadjuvant sintilimab combined with bevacizumab and chemotherapy followed by surgery in treating locally advanced and resectable NSCLC.
Histologically or cytologically confirmed, previously untreated and surgically resectable non-small cell lung cancer (stage II-IIIA, patients with squamous cell carcinoma or EGFR mutation should not be included);
Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
Satisfactory preoperative laboratory testing and adequate pulmonary function for surgery;
Patients approve and sign the informed consent.
Pancoast tumor, squamous cell carcinoma, large-cell carcinoma and sarcomatoid carcinoma;
Patients with active autoimmune disease or history of autoimmune disease;
Patients who have a condition requiring systemic treatment with either prednisone or other immunosuppressive medications;
Patients with a history of symptomatic interstitial lung disease;